# US 2025/0049927 A1 · Modified oligonucleotide-drug conjugate and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049927 A1
- Document ID: US20250049927A1
- Status: Published application
- Kind: A1
- Application number: 18/720,525
- Filed: 2022-11-08
- Published: 2025-02-13
- Earliest claimed: 2021-12-16
- Assignees: Interoligo Corporation
- Applicants: Interoligo Corporation.
- Inventors: JUNG HWAN LEE; JONG OOK LEE
- Web page: https://patentgrep.com/patent/US20250049927A1

## CPC

- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/07: Tetrapeptides
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A modified oligonucleotide including at least one modified nucleic acid, and a modified oligonucleotide-drug conjugate including a drug conjugated to the modified oligonucleotide. The modified oligonucleotide-drug conjugate exhibits high stability in the body and may exhibit an excellent anticancer effect. In a method for treating a cancer, the modified oligonucleotide-drug conjugate is administered to a subject in need thereof.

## Claims

### Claim at position 1

1: A modified oligonucleotide-drug conjugate comprising:
a modified oligonucleotide represented by Formula 1 below; and
a drug conjugated to deoxyuridine (dU) included in the modified oligonucleotide;
[Formula 1]
SEQ ID NO: 34)
5′-(M1)a-(N1)b-GGX1GGX2GGX3GGX4X5Y1X6GGX7GGX8GGX9GG-
(N2)c-(M2)d-3′
wherein, in Formula 1, X1 to X3 and X7 to X9 are each independently thymidine (T), or a modified nucleic acid represented by Formula 3 or Formula 4 below;
Y1 is deoxyguanosine (dG), or a modified nucleic acid represented by Formula 3 or Formula 4 below;
X4 to X6 are each independently thymidine (T), deoxyuridine (dU), or a modified nucleic acid represented by Formula 3 or Formula 4 below, and at least one of X4 to X6 is deoxyuridine (dU);
M1 and M2 are each independently a modified nucleic acid represented by Formula 3 or Formula 4 below;
N1 and N2 are each independently thymidine (T), deoxyuridine (dU), deoxycytidine (dC), or deoxyguanosine (dG);
a and d are each independently an integer of 0 to 10, but when all of X1 to X9 are thymidine (T) and Y1 is deoxyguanosine (dG), a and d are not 0 at the same time; and
b and c are each independently an integer of 0 to 10,
wherein, in Formulas 3 and 4,
R1 is hydrogen, halogen or a hydroxy group;
R2 is hydrogen, halogen or a hydroxy group; and
R3 is hydrogen, halogen, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group or C2-C6 haloalkenyl group, with a proviso excluding a case where R1 is hydrogen or a hydroxy group, R2 is hydrogen and R3 is hydrogen or methyl.

### Claim at position 2 (depends on 1)

2: The modified oligonucleotide-drug conjugate according to claim 1, wherein the modified nucleic acid represented by Formula 3 or Formula 4 above is selected from the group consisting of 5-fluorodeoxyuridine, 5-fluorouridine, 5-fluorodeoxycytidine, 5-fluorocytidine, 5-iododeoxyuridine, 5-iodouridine, 5-iododeoxycytidine, 5-iodocytidine, cytosine arabinoside, 2′,2′-difluoro-2′-deoxycytidine and bromovinyldeoxyuridine.

### Claim at position 3 (depends on 1)

3: The modified oligonucleotide-drug conjugate according to claim 1, wherein the drug is selected from the group consisting of paclitaxel, monomethyl auristatin E, monomethyl auristatin F, monomethyl auristatin D (MMAD), cytarabine, gemcitabine, maitansine, mertansine (DM1), DM4, calicheamicin and derivatives thereof, doxorubicin, duocarmycin and derivatives thereof, pyrrolobenzodiazepine (PBD), SN-38, α-amantine, tubulysin analog, cyclophosphamide, mecholrethamine, uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, carmustine, lomustine, streptozocin, busulfan, dacarbazine, temozolomide, thiotepa, altretamine, duocarmycin, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, triplatin tetranitrate, 5-fluorouracil, 6-mercaptopurine, capecitabine, cladribine, clofarabine, cystarbine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, thioguanine, camptothecin, topotecan, irinotecan, etoposide, teniposide, mitoxantrone, paclitaxel, docetaxel, izabepilone, vinblastine, vincristine, vindesine, vinorelbine, estramustine, maytansine, auristatin E, auristatin F and nemorubicin.

### Claim at position 4 (depends on 1)

4: The modified oligonucleotide-drug conjugate according to claim 1, wherein the drug and the deoxyuridine (dU) included in the modified oligonucleotide are conjugated by a linker L in which L1 and L2 are bound;
the L1 is selected from the group consisting of acrylamide-C2-NH2, C12-NH2, C3-NH2, acrylamide-C6-propanamide-SH, acrylamide-C6-NH2, C6-NH2, and C6-SH, which are selected from the group consisting of 5′-thiol-modifier C6, thiol-modifier C6 S—S, dithiol serinol, PC amino-modifier, 5′-amino-modifier C3, 5′-amino-modifier C6, 5′-amino-modifier C12, 5′-amino-modifier TEG, amino-modifier C2 dT, amino-modifier C6 dT, S-Bz-thiol-modifier C6-dT, phosphodiester bond and nucleotide, and then obtained through a deprotection process; and
the L2 is selected from the group consisting of maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-Val-Cit-PAB), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), succinic acid, hydrazone, peptide, disulfide, thioether, valine-citrulline, N-maleimidomethylcyclohexane-1-carboxylate (MCC), maleimidocaproyl, mercaptoacetamidocaproyl, N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP), N-succinimidyl 4-(2-pyridylthio) pentanoate (SPDB), phosphodiester bond and nucleotide.

### Claim at position 5 (depends on 1)

5: The modified oligonucleotide-drug conjugate according to claim 1, wherein the modified oligonucleotide consists of sequences selected from SEQ ID NO: 4 to SEQ ID NO: 10.

### Claim at position 6 (depends on 1)

6: A pharmaceutical composition for preventing or treating cancer comprising the modified oligonucleotide-drug conjugate according to claim 1.

### Claim at position 7 (depends on 6)

7: The pharmaceutical composition for preventing or treating cancer according to claim 6, wherein the cancer is selected from the group consisting of leukemia, lymphoma, breast cancer, liver cancer, gastric cancer, ovarian cancer, cervical carcinoma, glioma cancer, colon cancer, lung cancer, pancreatic cancer, prostate cancer, hepatoma, gastric adenocarcinoma, uterine cancer, bladder cancer, thyroid cancer, ovarian cancer, melanoma and cervical cancer.

### Claim at position 8

8: A modified oligonucleotide-drug conjugate comprising:
a modified oligonucleotide represented by Formula 2 below; and
a drug conjugated to at least one of 5′ and 3′ ends of the modified oligonucleotide;
[Formula 2]
(SEQ ID NO: 35)
5′-(M1)a-(N1)b-GGX1GGX2GGX3GGX4X5GX6GGX7GGX8GGX9GG-
(N2)c-(M2)d-3′
wherein, in Formula 2, X1 to X9 are each independently thymidine (T), or a modified nucleic acid represented by Formula 3 or Formula 4 below;
M1 and M2 are each independently a modified nucleic acid represented by Formula 3 or Formula 4 below;
N1 and N2 are each independently thymidine (T), deoxyuridine (dU), deoxycytidine (dC), or deoxyguanosine (dG);
a and d are each independently an integer of 0 to 10, but when all of X1 to X9 are thymidine (T), a and d are not 0 at the same time; and
b and c are each independently an integer of 0 to 10,
wherein, in Formulas 3 and 4,
R1 is hydrogen, halogen or a hydroxy group;
R2 is hydrogen, halogen or a hydroxy group; and
R3 is hydrogen, halogen, a C1-C6 alkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group or C2-C6 haloalkenyl group, with a proviso excluding a case where R1 is hydrogen or a hydroxy group, R2 is hydrogen and R3 is hydrogen or methyl.

### Claim at position 9 (depends on 8)

9: The modified oligonucleotide-drug conjugate according to claim 8, wherein the modified nucleic acid represented by Formula 3 or Formula 4 above is selected from the group consisting of 5-fluorodeoxyuridine, 5-fluorouridine, 5-fluorodeoxycytidine, 5-fluorocytidine, 5-iododeoxyuridine, 5-iodouridine, 5-iododeoxycytidine, 5-iodocytidine, cytosine arabinoside, 2′,2′-difluoro-2′-deoxycytidine and bromovinyldeoxyuridine.

### Claim at position 10 (depends on 8)

10: The modified oligonucleotide-drug conjugate according to claim 8, wherein the drug is selected from the group consisting of paclitaxel, monomethyl auristatin E, monomethyl auristatin F, monomethyl auristatin D (MMAD), cytarabine, gemcitabine, maitansine, mertansine (DM1), DM4, calicheamicin and derivatives thereof, doxorubicin, duocarmycin and derivatives thereof, pyrrolobenzodiazepine (PBD), SN-38, α-amantine, tubulysin analog, cyclophosphamide, mecholrethamine, uramustine, melphalan, chlorambucil, ifosfamide, bendamustine, carmustine, lomustine, streptozocin, busulfan, dacarbazine, temozolomide, thiotepa, altretamine, duocarmycin, cisplatin, carboplatin, nedaplatin, oxaliplatin, satraplatin, triplatin tetranitrate, 5-fluorouracil, 6-mercaptopurine, capecitabine, cladribine, clofarabine, cystarbine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, thioguanine, camptothecin, topotecan, irinotecan, etoposide, teniposide, mitoxantrone, paclitaxel, docetaxel, izabepilone, vinblastine, vincristine, vindesine, vinorelbine, estramustine, maytansine, auristatin E, auristatin F and nemorubicin.

### Claim at position 11 (depends on 8)

11: The modified oligonucleotide-drug conjugate according to claim 8, wherein the drug and at least one of the 5′ and 3′ ends of the modified oligonucleotide represented by Formula 2 above are conjugated by a linker L in which L1 and L2 are bound;
the L1 is selected from the group consisting of (acrylamide)-C2-NH2, C12-NH2, C3-NH2, acrylamide-C6-propanamide-SH, acrylamide-C6-NH2, C6-NH2, and C6-SH, which are selected from the group consisting of 5′-thiol-modifier C6, thiol-modifier C6 S—S, dithiol serinol, PC amino-modifier, 5′-amino-modifier C3, 5′-amino-modifier C6, 5′-amino-modifier C12, 5′-amino-modifier TEG, amino-modifier C2 dT, amino-modifier C6 dT, S-Bz-thiol-modifier C6-dT, phosphodiester bond and nucleotide, and then obtained through a deprotection process; and
the L2 is selected from the group consisting of maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-Val-Cit-PAB), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), succinic acid, hydrazone, peptide, disulfide, thioether, valine-citrulline, N-maleimidomethylcyclohexane-1-carboxylate (MCC), maleimidocaproyl, mercaptoacetamidocaproyl, N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP), N-succinimidyl 4-(2-pyridylthio) pentanoate (SPDB), phosphodiester bond and nucleotide.

### Claim at position 12 (depends on 8)

12: The modified oligonucleotide-drug conjugate according to claim 8, wherein the modified oligonucleotide consists of a sequence selected from SEQ ID NO: 11 or SEQ ID NO: 12.

### Claim at position 13 (depends on 8)

13: A pharmaceutical composition for preventing or treating cancer comprising the modified oligonucleotide-drug conjugate according to claim 8.

### Claim at position 14 (depends on 8)

14: A method for treating cancer, the method comprising administering to a subject in need thereof a composition comprising the modified oligonucleotide-drug conjugate according to claim 8.

### Claim at position 15 (depends on 1)

15: A method for treating cancer, the method comprising administering to a subject in need thereof a composition comprising the modified oligonucleotide-drug conjugate according to claim 1.
